Skip to content

Ocular Manifestations in Rheumatic Diseases

Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03753893
Enrollment
5000
Registered
2018-11-27
Start date
2013-05-01
Completion date
2021-11-01
Last updated
2022-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amaurosis Fugax, Blindness, Chorioretinitis, Choroid Hemorrhage, Conjunctivitis, Eye Hemorrhage, Iridocyclitis, Keratoconjunctivitis Sicca, Macular Edema, Optic Neuritis, Orbital Diseases, Papilledema, Retinal Artery Occlusion, Retinal Vein Occlusion, Retinitis, Scleritis, Uveitis, Xerophthalmia

Brief summary

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

Detailed description

For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax. These terms were searched in the context of a corresponding inflammatory disease on Medline, Cochrane and Web of Science from their inception (1966, 1991 and 1990 respectively) until the point of study completion. Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in an inflammatory rheumatic disease. Studies were excluded if they were review articles, case reports where all patients experienced the same ocular comorbidity, if different comorbidities were not grouped independently, and if the study reported on fewer than 20 patients. When the same study cohort was used in more than one analysis, the most recent or largest sample-size study was included. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to assess the quality of cohort, case-control, and cross-sectional studies.

Interventions

no intervention used

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in inflammatory rheumatic disease

Exclusion criteria

* review articles, * case reports where all patients experienced the same ocular comorbidity * if different comorbidities were not grouped independently * if the study reported on fewer than 20 patients

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of ocular manifestations of inflammatory rheumatic diseasesdata is collected once per year up to 2020Prevalence of ocular manifestations of inflammatory rheumatic diseases

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026